

# Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

<https://marketpublishers.com/r/G1B8C5D4F99EN.html>

Date: April 2018

Pages: 470

Price: US\$ 3,000.00 (Single User License)

ID: G1B8C5D4F99EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” report highlights:

Global Malignant Melanoma Drug Market Overview

Dosage, Price & Patent Insight

Global Malignant Melanoma Drug Clinical Pipeline: 197 Drugs

Marketed Malignant Melanoma Drug Clinical Insight: 25 Drugs

Sales Analysis of Global Melanoma Therapeutics

Regional Analysis of the Melanoma Drug Market

Melanoma occurs due to mutations in the skin cells which ultimately lead to the formation of malignant tumors. These tumors commonly originate in the pigment-producing melanocytes in the basal layer of the epidermis. Being an advanced form of skin cancer, it is the cause of maximum number of skin cancer deaths. An insight into the prevalence of melanoma shows a rising trend amplified by the use of tanning beds and increased exposure of skin to ultraviolet rays in regions like the US, Europe & Australia which currently show much higher prevalence than the rest of the world.

In spite of melanoma being a fatal form of skin cancer, its early detection makes it easily treatable. The melanoma market is flooded with traditional therapeutic approaches of chemotherapy, radiation therapy and surgery with many advanced therapies slowly entering the market. However, each of the traditional methods have several limitations; thus leading to an increased need for better and efficient therapeutics.

Current market trends indicate that the malignant melanoma market is slowly shifting to advanced and targeted therapeutic methods such as vaccines and immunotherapy. The recent FDA approvals of six biologics within six years has been a boost to the growth of the malignant melanoma market with many key players investing heavily on the research and development of therapeutics that have shown promising therapeutic results in clinical studies of malignant melanoma.

The targeted therapy segment of the malignant melanoma market is anticipated to be the most promising market of the future due to its high efficacy with minimum side effects. Further, sales analysis and future projections of existing therapeutics show exponential growth for the newly introduced biologics like Opdivo and cotellic due to a multifold increase in adoption rate, positive post marketing response and feedback from users.

The US currently leads the global malignant melanoma market due to a large patient base, easy availability and affordability of the newly introduced biologics followed by Europe. Other regions such as Australia and New Zealand have also contributed significantly to the current market size. However, the increasing patient base in highly populated regions like China and India is estimated to shift the market size to these Asian regions by the year 2024.

Overall, the global melanoma market is anticipated to expand in value from US\$ close to 5 Billion in 2016 to an estimated US\$ 14 billion by 2024, representing a robust Compound Annual Growth Rate (CAGR) of 12%. The advancement in research and development of therapeutics, early entry and dominance of immunotherapeutics, strong investor base and a robust clinical pipeline ensures a bright future for the key players involved in the segment.

Kuick Research report on the global malignant melanoma is based on an in-depth analysis of the current market trends, Opportunities and Other dynamics that may have a significant impact on the market. Special emphasis has been put on the collection and analysis of latest data that will influence the market in the present and the future.

Further, analysis of sales data, patent expiry, Cost analysis of therapeutics and collaboration between industries has been used to devise an accurate and efficient projection regarding the future of malignant melanoma market which clearly indicates it to be a key market in the future of skin cancer therapy.

## Contents

### **1. MALIGNANT MELANOMA - COMMON CANCER WITH HIGH MORTALITY**

- 1.1 Prologue to Malignant Melanoma
- 1.2 Risk Factors Associated with Melanoma
- 1.3 Overview of Melanoma Diagnosis & Therapy

### **2. ANALYSIS REGARDING THE GLOBAL PREVALENCE OF MELANOMA**

- 2.1 Prevalence in the US
- 2.2 Prevalence in Europe & Rest of the World

### **3. MELANOMA MARKET ANALYSIS BY DIAGNOSIS & SCREENING**

- 3.1 Stages of melanoma Diagnosis & Treatment Options
- 3.2 Cost Analysis of Melanoma Screening

### **4. MALIGNANT MELANOMA THERAPY & COST ANALYSIS BY STAGE**

- 4.1 Stage
- 4.2 Stage I
- 4.3 Stage II Melanoma
- 4.4 Stage III Melanoma
- 4.5 Stage IV Melanoma
- 4.6 Recurrent Melanoma

### **5. MALIGNANT MELANOMA MANAGEMENT & THERAPY - COST ANALYSIS BY TREATMENT MODALITY**

- 5.1 Surgery
- 5.2 Radiation Therapy
- 5.3 Chemotherapy
  - 5.3.1 Decarbazine
  - 5.3.2 Temozolomide
  - 5.3.3 Taxol (Paclitaxel & Carboplatin)
- 5.4 Biological Therapy/Targeted Therapies
  - 5.4.1 T-VEC (Imlygic®)
  - 5.4.2 Nivolumab (Opdivo®)

- 5.4.3 Ipilimumab (Yervoy®)
- 5.4.4 Pembrolizumab (Keytruda®)
- 5.4.5 Peginterferon alpha 2-b (Sylatron®)
- 5.4.6 Interleukin-2 (IL-2; Proleukin®)

## 5.5 Inhibitors in Malignant Melanoma Treatment

- 5.5.1 Vemurafenib (Zelboraf®) + Cobimetinib (Cotellic®)
- 5.5.2 Dabrafenib (Tafinlar®) + Trametinib (Mekinist®)
- 5.5.3 Vemurafenib (Zelboraf®)

## 6. SALES ANALYSIS OF GLOBAL MELANOMA THERAPEUTICS

- 6.1 Global- Melanoma Chemotherapy Drug Sales
- 6.2 Melanoma Targeted Therapy Sales Analysis

## 7. MALIGNANT MELANOMA THERAPY – MARKET TREND & SCOPE ANALYSIS

- 7.1 Overview - Screening & Traditional Therapy Market
- 7.2 Modern Melanoma Therapeutics Market

## 8. GLOBAL MALIGNANT MELANOMA DRUG CLINICAL PIPELINE OVERVIEW

## 9. REGIONAL ANALYSIS OF THE MELANOMA DRUG MARKET

- 9.1 North America
  - 9.1.1 US
  - 9.1.2 Canada
- 9.2 Europe
- 9.3 Asia Pacific
  - 9.3.1 Japan
  - 9.3.2 China
  - 9.3.3 Australia
- 9.4 Middle East & Africa (MEA)

## 10. GLOBAL MELANOMA DRUG MARKET DYNAMICS

- 10.1 Driving Factors of the Malignant Melanoma Drug Market
- 10.2 Restraining Factors of the Melanoma Drug Market

## 11. FUTURE FORECAST REGARDING THE MALIGNANT MELANOMA DRUG

## **MARKET**

### **12. GLOBAL MALIGNANT MELANOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE**

- 12.1 Unknown
- 12.2 Research
- 12.3 Preclinical
- 12.4 Clinical
- 12.5 Phase-I
- 12.6 Phase-I/II
- 12.7 Phase-II
- 12.8 Phase-II/III
- 12.9 Phase-III
- 12.10 Preregistration
- 12.11 Registered

### **13. MARKETED MALIGNANT MELANOMA DRUG CLINICAL INSIGHT**

### **14. COMPETITIVE ANALYSIS**

- 14.1 AVAX Technologies
- 14.2 Biogen Idec
- 14.3 BioVex
- 14.4 Bristol-Myers Squibb
- 14.5 Chiron
- 14.6 Enzon Pharmaceuticals
- 14.7 GlaxoSmithKline
- 14.8 Lorus Therapeutics
- 14.9 Medarex
- 14.10 Merck
- 14.11 Ono Pharmaceutical
- 14.12 Plexxikon
- 14.13 Reliance Life Sciences
- 14.14 Roche

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Historical Timeline of Melanoma
- Figure 1-2: Malignant Melanoma - Risk Factors
- Figure 1-3: Difference between Normal Skin Lesions & Melanoma
- Figure 1-4: Melanoma Development in Action
- Figure 1-5: Melanoma- Biopsy Types
- Figure 1-6: Biopsy Techniques used for the Diagnosis of melanoma
- Figure 2-1: US - Melanoma Prevalence by Gender (Number of patients), 2018
- Figure 2-2: 5 Year Survival Rate- by Stage of Therapy (%)
- Figure 2-3: Europe - Regional Mortality by Melanoma (number of Deaths per 100,000 patients), 2012-2016
- Figure 2-4: Global- Melanoma Prevalence (per 100,000 Individuals), 2016
- Figure 3-1: Cost Analysis - Melanoma Screening Cost (US\$), 2018
- Figure 3-2: Australia - Melanoma Management & Therapy Cost Analysis (US\$/Patient), 2018
- Figure 4-1: Comparative Price Analysis- by Body Part affected by Melanoma, 2018
- Figure 4-2: -Melanoma Stage 0 – Estimated Treatment Cost (US\$), 2018
- Figure 4-3: Stage I - Estimated Treatment Cost (US\$), 2018
- Figure 4-4: Melanoma Treatment Efficacy (Stage II) by Treatment Modality (%), 2018
- Figure 4-5: Stage II -Estimated Cost Analysis by Technique (US\$), 2018
- Figure 4-6: Stage III/IV Treatment Modality Approach
- Figure 5-1: Surgery-Average Cost Analysis Range by Stage (US\$/Patient), 2018
- Figure 5-2: Surgery - Average Cost Analysis (US\$), 2016
- Figure 5-3: Radiation Therapy - Average Cost Analysis by Melanoma Location (US\$), 2018
- Figure 5-4: Dosage Analysis - Decarbazine & Temozolomide(mg/kg)
- Figure 5-5: Price Analysis - Decarbazine & Temozolomide(US\$/100mg), 2018
- Figure 5-6: Temozolomide - Price Analysis (US\$), 2018
- Figure 5-7: Temozolomide - Price Analysis (US\$/mg), 2018
- Figure 5-8: Cost Analysis - Melanoma Targeted Therapy (US\$/Month), 2018
- Figure 5-9: T-VEC: Mechanism of Action
- Figure 5-10:T-VEC- Dosage Analysis(ml/ Plaque Forming Unit\*)
- Figure 5-11: Imlygic - Vial & Therapy Cost Analysis (US\$), 2018
- Figure 5-12: Nivolumab + Ipilimumab-Dosage Analysis (mg)
- Figure 5-13: Yervoy- Mechanism of Action in Melanoma Therapy
- Figure 5-14: Nivolumab & Ipilimumab- Drug Price Analysis (US\$/mg), 2018

- Figure 5-15: Keytruda -Dosage Analysis (mg/kg)
- Figure 5-16: Sylatron - Dosage Analysis (mcg/kg body weight/week)
- Figure 5-17: Interleukin-2 Action Mechanism
- Figure 5-18: Zelboraf & Cobimetinib - Dosage Analysis (mg)
- Figure 5-19: Zelboraf & Cotellic – Price Analysis (US\$/Month), 2018
- Figure 5-20: Tafinlar- Dosage Analysis (mg Twice Daily)
- Figure 5-21: Mekinist - Dosage Analysis (mg once daily)
- Figure 6-1: Global - Melanoma Chemotherapeutics Sales (US\$ Million), 2014-2016
- Figure 6-2: Global - Melanoma Biological Therapeutics Sales (US\$ Million), 2015-2016
- Figure 7-1: Global - Melanoma Market Segmentation by Diagnosis & Therapy (%), 2018
- Figure 7-2: Global- Melanoma Diagnosis Market Forecast (US\$ Billion), 2016-2024
- Figure 7-3: Global - Melanoma Chemotherapy Drug Sales Forecast (US\$ Billion), 2018-2024
- Figure 7-4: Global - Melanoma Surgery Market Forecast (US\$ Million), 2018-2024
- Figure 7-5: Global- Radiation Melanoma Therapy Forecast (US\$ Million), 2018-2024
- Figure 7-6: Global – Melanoma Targeted Therapy Market Forecast, 2016-2024
- Figure 8-1: Global - Malignant Melanoma Pipeline by Phase (%), 2018 till 2024
- Figure 8-2: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
- Figure 8-3: Global - Malignant Melanoma Pipeline by Phase (%),2018 till 2024
- Figure 8-4: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
- Figure 9-1: US - Melanoma Therapeutics Market Forecast (US\$ Billion), 2016-2024
- Figure 9-2: Canada- Melanoma Therapeutics Market Forecast (US\$ Million), 2016-2024
- Figure 9-3: Europe - Treatment Modality Used in Melanoma Therapy, 2016-2017
- Figure 10-1: Driving Factors of the Global Melanoma Drug Market
- Figure 10-2: Melanoma Drug Market - Growth Restraining Factors



## List Of Tables

### LIST OF TABLES

Table 3-1: Melanoma Stage, Description & Available Treatment Options

## I would like to order

Product name: Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

Product link: <https://marketpublishers.com/r/G1B8C5D4F99EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1B8C5D4F99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970